HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris’ Upjohn Breaking Taboo Around Erectile Dysfunction With UK PR Campaign

Executive Summary

Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals. 

You may also be interested in...



Why Did Germany Reject Sildenafil OTC Switch?

Sildenafil was rejected at Germany’s independent switch committee’s most recent meeting. HBW Insight examines some of the arguments for and against the switch put forward by the regulator, members of the committee and the applicant, as recorded in the recently published minutes.

Top 10 UK OTC Marketing Stories 2020: Digital Health And Probiotics Lead The Way

HBW Insight's countdown of the top-10 most read UK OTC marketing stories in 2020 includes launches and campaigns from consumer health players such as Sanofi, J&J, GSK and Bayer, amongst others.

Giddy Emphasizes Shape To Differentiate Its OTC ED Device In Crowded And Growing Market

Designed to decrease venous leak from the corpora cavernosa, Giddy makes its Eddie device in oblong shape that opens at one point into two S-forms. Elastic bands are placed around the S-forms to pull the shape together at variable tensions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel